Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

What's In The Cards For Bayer (BAYRY) This Earnings Season?

By Zacks Investment ResearchStock MarketsNov 11, 2018 09:04PM ET
www.investing.com/analysis/whats-in-the-cards-for-bayer-bayry-this-earnings-season-200358199
What's In The Cards For Bayer (BAYRY) This Earnings Season?
By Zacks Investment Research   |  Nov 11, 2018 09:04PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Bayer AG (DE:BAYGN) (OTC:BAYRY) is scheduled to report third-quarter 2018 results on Nov 13, before market open.

Bayer’s shares have decreased 35.2% so far this year against the industry’s increase of 8.3%.

The company delivered positive earnings surprise in two of the last four quarters and missed expectations twice. The average positive earnings surprise in the last four quarters is 19.19%. In the last reported quarter, Bayer delivered a negative surprise of 4.17%.

Let’s see how things are shaping up for this quarter.

Factors Likely to Influence Q3 Results

Bayer is primarily focused on the Life Science businesses. However, it reports under four business segments – Pharmaceuticals, Consumer Health, Crop Science and Animal Health.

Sales at the pharmaceutical segment rose in the first half of 2018 driven by key products like Xarelto, Eylea, Xofigo, Stivarga and Adempas. In August, Bayer along with its partners, Johnson & Johnson (NYSE:JNJ) and Regeneron (NASDAQ:REGN) , announced the approval for label expansion of Xarelto and Eylea, respectively, in Europe. The expanded patient population for these drugs bodes well for Bayer as it is likely to boost sales. Moreover, approval for new hemophilia drug, Jivi, in the United States will also boost segment sales. However, sales of Kogenate and Betaferon may continue to decline due to supply constraints and increasing competition, respectively.

Crop Science segment also performed well in the first six months of the year. Sales grew rapidly during the second quarter with the inclusion of pro-rata sales from Mosanto acquisition completed in early June. This acquisition will add significant amount of sales in the third quarter and boost Bayer’s presence in the seed business.

Sales growth in Animal Health segment is also likely to continue this quarter. Although sales at Consumer Health segment declined in the first half of 2018, we may see a turnaround in the second half. Bayer maintained it growth forecast in the range of 3%-4% for this segment on its second-quarter earnings call.

The company has been divesting certain businesses, in line with its strategy to focus on Life Science business. However, the company will lose significant sales due to divestures. The company stated that divestment of selected businesses to BASF will reduce anticipated sales by approximately €1 billion for 2018.

The Zacks Consensus Estimate for third-quarter sales and earnings is pegged at $11.31 billion and 41 cents, respectively.

Earnings Whispers

Our proven model does not conclusively show that Bayer is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.

Earnings ESP: Its Earnings ESP is +20.99%. The Zacks Consensus Estimate is pegged at 41 cents while the Most Accurate Estimate is pegged at 49 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: Bayer has a Zacks Rank #4 (Sell).

Note that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.

Stock to Consider

Here is a biotech stock that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat this quarter.

Galapagos NV (NASDAQ:GLPG) is expected to release its third-quarter results on Nov 13. The company has an Earnings ESP of +229.73% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>



Johnson & Johnson (JNJ): Free Stock Analysis Report

Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report

Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report

Galapagos NV (GLPG): Free Stock Analysis Report

Original post
What's In The Cards For Bayer (BAYRY) This Earnings Season?
 

Related Articles

What's In The Cards For Bayer (BAYRY) This Earnings Season?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email